2006
DOI: 10.1200/jco.2006.24.18_suppl.1527
|View full text |Cite
|
Sign up to set email alerts
|

An update of phase II results from RTOG 0211: A phase I/II study of gefitinib with radiotherapy in newly diagnosed glioblastoma

Abstract: 1527 Background: The epidermal growth factor receptor (EGFR) pathway is commonly deregulated in GBMs and its activity has been associated with treatment resistance in preclinical models. Accordingly, the Radiation Therapy Oncology Group (RTOG) recently conducted a Phase I/II study of Gefitinib, an EGFR tyrosine kinase inhibitor, in combination with radiotherapy for newly-diagnosed glioblastoma (GBM) patients. Methods: 178 GBM patients were entered on RTOG 0211 (Phase I: 31 patients and Phase II: 147 patients)… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2008
2008
2010
2010

Publication Types

Select...
4
2
1

Relationship

0
7

Authors

Journals

citations
Cited by 21 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…Studies of erlotinib (EGFR), gefitinib (EGFR), and lapatinib (ErbB2/HER2, EGFR) have failed to demonstrate any significant survival benefit compared with historical controls. [78][79][80][81][82][83][84][85][86] The combination of EGFR inhibitors with other therapies is discussed later in this article.…”
Section: Epidermal Growth Factor Receptor Inhibitorsmentioning
confidence: 99%
“…Studies of erlotinib (EGFR), gefitinib (EGFR), and lapatinib (ErbB2/HER2, EGFR) have failed to demonstrate any significant survival benefit compared with historical controls. [78][79][80][81][82][83][84][85][86] The combination of EGFR inhibitors with other therapies is discussed later in this article.…”
Section: Epidermal Growth Factor Receptor Inhibitorsmentioning
confidence: 99%
“…A large Phase I/II study performed by the Radiation Therapy Oncology Group (RTOG) assessed the use of gefitinib and radiation for de novo GBMs. Interim results suggest that there was no significant survival advantage gained in patients treated with gefitinib, however, molecular analyses are underway to determine which GBM patients derive the greatest benefit from this TKI168 .…”
mentioning
confidence: 99%